Page last updated: 2024-11-04

benzyl benzoate

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Occurs in Manufacturing Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

benzyl benzoate: structure; acarosan, a moist powder composed of wetted cellulose and benzyl benzoate, is used on carpets as an acaricide [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

benzyl benzoate : A benzoate ester obtained by the formal condensation of benzoic acid with benzyl alcohol. It has been isolated from the plant species of the genus Polyalthia. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2345
CHEMBL ID1239
CHEBI ID41237
SCHEMBL ID3038
MeSH IDM0049438

Synonyms (184)

Synonym
smr000471875
MLS001066412
AC-17033
LS-14279
nsc8081
benzylets
120-51-4
benzyl alcohol benzoic ester
benzyl benzenecarboxylate
venzonate
nsc-8081
scabitox
novoscabin
scabiozon
scabagen
ascabiol
scabide
colebenz
benzyl phenylformate
benzyl benzoate
benzoic acid, phenylmethyl ester
wln: rvo1r
peruscabin
scobenol
benzoic acid, benzyl ester
ascabin
scabanca
vanzoate
benylate
KBIO1_000204
DIVK1C_000204
fema number 2138
hsdb 208
benzylis benzoas
benzylbenzenecarboxylate
antiscabiosum
nsc 8081
benzyl benzoate (natural)
peruscabina
ai3-00523
einecs 204-402-9
caswell no. 082
benzylester kyseliny benzoove [czech]
brn 2049280
benzylum benzoicum
benzoesaeurebenzylester
epa pesticide chemical code 009501
fema no. 2138
bengal
SPECTRUM_001240
IDI1_000204
BSPBIO_003494
benzoic acid,benzyl ester
inchi=1/c14h12o2/c15-14(13-9-5-2-6-10-13)16-11-12-7-3-1-4-8-12/h1-10h,11h
bzm ,
benzoic acid phenylmethylester
benzyl benzoate, natural, >=99%, fcc, fg
benzyl benzoate, >=99%, fcc, fg
benzyl benzoate, meets usp testing specifications
phenylmethyl benzoate
CHEBI:41237 ,
DB00676
1DZM
benzevan
acarobenzyl
D01138
benzyl benzoate (jp17/usp)
benylate (tn)
SPECTRUM5_001128
NCGC00094981-03
NCGC00094981-01
NCGC00094981-02
KBIO2_004288
KBIO3_002714
KBIO2_001720
KBIO2_006856
KBIOSS_001720
KBIOGR_001186
NINDS_000204
SPBIO_000543
SPECTRUM4_000773
SPECTRUM3_001757
SPECTRUM2_000532
SPECTRUM1503002
NCGC00094981-04
MLS001336003
MLS001336004
benzylbenzoate
benzoic acid benzyl ester
benzyl benzoate, reagentplus(r), >=99.0%
HMS2092F20
B0064
bdbm50134035
CHEMBL1239 ,
AKOS003495939
HMS500K06
HMS1921P16
A19449
benzoic acid benzyl ester; benzoic acid phenylmethyl ester
NCGC00094981-05
acarosan
tox21_303418
dtxsid8029153 ,
NCGC00257502-01
cas-120-51-4
dtxcid809153
tox21_201337
NCGC00258889-01
nsc758204
pharmakon1600-01503002
nsc-758204
tox21_111372
HMS2269D24
S4599
CCG-39578
venzoate
benzylester kyseliny benzoove
unii-n863nb338g
4-09-00-00307 (beilstein handbook reference)
ec 204-402-9
benzyl benzoate [usp:jan]
n863nb338g ,
FT-0622708
benzyl benzoate [usp-rs]
benzyl benzoate [ep monograph]
benzyl benzoate [who-dd]
benzyl benzoate [usp monograph]
benzyl benzoate [mi]
benzyl benzoate [ii]
benzyl benzoate [fcc]
benzyl benzoate [hsdb]
benzyloxy phenyl ketone
benzylis benzoas [who-ip latin]
benzyl benzoate [jan]
benzyl benzoate [orange book]
benzyl benzoate [mart.]
benzyl benzoate [fhfi]
benzyl benzoate [usp impurity]
benzyl benzoate [inci]
benzyl benzoate [who-ip]
benzyl benzoate [ep impurity]
SCHEMBL3038
NCGC00094981-07
tox21_111372_1
Q-200696
347840-01-1
HY-B0935
AB00052298_07
mfcd00003075
benzoate de benzyle
benzyl benzoate, analytical standard
benzyl benzoate, >=99%
SR-01000763773-2
sr-01000763773
benzyl benzoate, united states pharmacopeia (usp) reference standard
benzyl benzoate, certified reference material, tracecert(r)
benzyl benzoate, saj first grade, >=98.0%
benzyl benzoate, saj special grade, >=99.0%
benzyl benzoate, tested according to ph.eur.
benzyl benzoate, for synthesis, 99.0%
benzyl benzoate, pharmaceutical secondary standard; certified reference material
benzyl benzoate, vetec(tm) reagent grade, 98%
benzoic acid-benzyl ester
benzoic acid-benzyl ester 5000 microg/ml in hexane
SBI-0051748.P002
Q413755
Z19825582
BRD-K52072429-001-06-1
A14577
STL183088
benzyl-benzoate
benzyl-d5 benzoate
benzoic acid-benzyl ester 100 microg/ml in acetonitrile
EN300-7323193
benzyl benzoate (usp impurity)
benzyl benzoate (mart.)
benzyl benzoate (usp-rs)
benzyl benzoate (usp monograph)
benzyl benzoate (usp:jan)
benzyl benzoate (ep impurity)
benzyl benzoate (ii)
benzoesaurebenzylester
benzyl benzoat
benzyl benzoate (ep monograph)

Research Excerpts

Effects

ExcerptReferenceRelevance
"Benzyl benzoate (BB), which has been widely used to kill scabies mites and is known to kill mites of the genus Dermatophagoides, has been used as a method of treating carpets."( Benzyl benzoate moist powder: investigation of acaricidal [correction of acarical] activity in cultures and reduction of dust mite allergens in carpets.
Chapman, MD; Diduch, KB; Domson, P; Hayden, ML; Heymann, PW; Platts-Mills, TA; Rose, G, 1992
)
2.45

Treatment

ExcerptReferenceRelevance
"Treatment with benzyl benzoate was repeated until the house dust samples were negative for house dust mite guanine."( The clinical effect of environmental control of house dust mites in 60 house dust mite-sensitive dogs.
Swinnen, C; Vroom, M, 2004
)
0.66

Toxicity

benzyl alcohol, benzoic acid and its salts, and benzyl benzoate are safe in the present practices of use.

ExcerptReferenceRelevance
"We found no evidence of adverse effects on pregnancy outcome due to topical 25% BBL or 4% permethrin."( Safety of benzyl benzoate lotion and permethrin in pregnancy: a retrospective matched cohort study.
Ashley, EA; Carrara, VI; Jay, MP; Lee, SJ; McGready, R; Mytton, OT; Nosten, F; Roberts, CH; Singhasivanon, P; Thwai, KL; Wiangambun, T, 2007
)
0.74
"7 times more toxic than benzyl benzoate (43."( Fumigant toxicity of cassia bark and cassia and cinnamon oil compounds to Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
Ahn, YJ; Kim, HK; Yun, YK, 2008
)
0.65
"69 microg/cm2) were the most toxic compounds, followed by methyl eugenol (5."( Toxicity of basil oil constituents and related compounds and the efficacy of spray formulations to Dermatophagoides farinae (Acari: Pyroglyphidae).
Ahn, YJ; Hwang, KN; Kim, JR; Kim, JY; Perumalsamy, H, 2014
)
0.4
" After reviewing newly available data, it was concluded that benzyl alcohol, benzoic acid and its salts, and benzyl benzoate are safe in the present practices of use and concentration described in this safety assessment."( Safety Assessment of Benzyl Alcohol, Benzoic Acid and its Salts, and Benzyl Benzoate.
Andersen, FA; Belsito, DV; Bergfeld, WF; Hill, RA; Johnson, W; Klaassen, CD; Liebler, DC; Marks, JG; Shank, RC; Slaga, TJ; Snyder, PW,
)
0.58
" Direct and network meta-analyses were applied to 13 antiscabietic agents on 3 outcomes (cure, persistent itching, and adverse events)."( Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials.
Anothaisintawee, T; Attia, J; Rattanasiri, S; Thadanipon, K; Thakkinstian, A, 2019
)
0.51
" Combination permethrin plus oral ivermectin was ranked highest in terms of cure, topical ivermectin in terms of persistent itching, and synergized pyrethrins in terms of adverse events."( Efficacy and safety of antiscabietic agents: A systematic review and network meta-analysis of randomized controlled trials.
Anothaisintawee, T; Attia, J; Rattanasiri, S; Thadanipon, K; Thakkinstian, A, 2019
)
0.51

Bioavailability

ExcerptReferenceRelevance
" The dermatokinetic studies confirmed better permeation and enhanced skin bioavailability of BB to epidermis as well as dermis vis-à-vis the conventional product."( Benzyl Benzoate-Loaded Microemulsion for Topical Applications: Enhanced Dermatokinetic Profile and Better Delivery Promises.
Dhankar, G; Katare, OP; Raza, K; Sharma, G; Thakur, K, 2016
)
1.88
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51

Dosage Studied

ExcerptRelevanceReference
"8 mg), CPK activity was shown to depend on both the type of dosage form and, in the case of nanocapsules, on the chemical nature of the central oily core."( Poly(rac-lactide) nanocapsules containing diclofenac: protection against muscular damage in rats.
Barratt, G; Devissaguet, JP; Fessi, H; Guterres, SS; Puisieux, F, 2000
)
0.31
" The observed responses varied according to dosage and mite species."( Acaricidal activity and function of mite indicator using plumbagin and its derivatives isolated from Diospyros kaki Thunb. roots (Ebenaceae).
Lee, CH; Lee, HS, 2008
)
0.35
" All EOs were repellent, followed a dose-response relationship, and had bioactivity similar to or better than that of commercial compound IR3535."( Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
Caballero-Gallardo, K; Olivero-Verbel, J; Stashenko, EE, 2011
)
0.37
"Persistence of infection appears to be linked to: (1) insufficient treatment of close contacts; (2) absence of a second treatment between days 7 and 14; (3) insufficient efficacy of the available treatments, doubtless due to multiple factors (intrinsic resistance of Sarcoptes, failure to repeat treatment, poor explanation of methods for dosing and application, and oral intake of treatments)."( [Therapeutic failure in scabies: An observational study].
Baumstarck, K; Bentaleb, N; De Sainte Marie, B; Gaudy-Marqueste, C; Grob, JJ; Hesse, S; Loundou, A; Mallet, S; Monestier, S; Richard, MA, 2016
)
0.43
" We unexpectedly discover a new class of aggregating ligands that exhibit negligible interactions with proteins but act as competitive sinks for the free inhibitor, resulting in bell-shaped dose-response curves."( Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
Ahmed, R; Boulton, S; Cheng, X; Melacini, G; Selvaratnam, R; Van, K, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Occurs in Manufacturing (14 Items)

ItemProcessFrequency
Snackscore-ingredient4
en:open-beauty-factscore-ingredient4
déodorantcore-ingredient4
Non food productscore-ingredient3
Open Beauty Factscore-ingredient3
Non alimentairecore-ingredient2
Caramel cashewscore-ingredient1
Open Products Factscore-ingredient1
Air freshenercore-ingredient1
Cosmétiquescore-ingredient1
de:deocore-ingredient1
de:Körperpflegecore-ingredient1
Aceite de bebecore-ingredient1
Vücut spreyicore-ingredient1

Roles (3)

RoleDescription
scabicideAn acaricide that kills mites of the genus Sarcoptes.
acaricideA substance used to destroy pests of the subclass Acari (mites and ticks).
plant metaboliteAny eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
benzoate esterEsters of benzoic acid or substituted benzoic acids.
benzyl ester
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (4)

PathwayProteinsCompounds
volatile benzenoid biosynthesis I (ester formation)119
salicortin biosynthesis020
benzoate biosynthesis I (CoA-dependent, u03B2-oxidative)119
volatile esters biosynthesis (during fruit ripening)220

Protein Targets (32)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, TYROSYL-DNA PHOSPHODIESTERASEHomo sapiens (human)Potency17.78280.004023.8416100.0000AID485290
Chain A, JmjC domain-containing histone demethylation protein 3AHomo sapiens (human)Potency50.11870.631035.7641100.0000AID504339
Chain A, Ferritin light chainEquus caballus (horse)Potency22.38725.623417.292931.6228AID485281
LuciferasePhotinus pyralis (common eastern firefly)Potency12.84160.007215.758889.3584AID1224835; AID624030
RAR-related orphan receptor gammaMus musculus (house mouse)Potency18.35810.006038.004119,952.5996AID1159521; AID1159523
USP1 protein, partialHomo sapiens (human)Potency89.12510.031637.5844354.8130AID504865
TDP1 proteinHomo sapiens (human)Potency20.59620.000811.382244.6684AID686979
GLI family zinc finger 3Homo sapiens (human)Potency25.24300.000714.592883.7951AID1259369; AID1259392
glucocorticoid receptor [Homo sapiens]Homo sapiens (human)Potency48.97220.000214.376460.0339AID720692
retinoic acid nuclear receptor alpha variant 1Homo sapiens (human)Potency9.28420.003041.611522,387.1992AID1159552; AID1159553; AID1159555
estrogen-related nuclear receptor alphaHomo sapiens (human)Potency28.94570.001530.607315,848.9004AID1224841; AID1224848; AID1224849; AID1259401; AID1259403
farnesoid X nuclear receptorHomo sapiens (human)Potency1.58490.375827.485161.6524AID588527
estrogen nuclear receptor alphaHomo sapiens (human)Potency24.62530.000229.305416,493.5996AID743069
thyroid stimulating hormone receptorHomo sapiens (human)Potency10.90390.001628.015177.1139AID1224843
v-jun sarcoma virus 17 oncogene homolog (avian)Homo sapiens (human)Potency30.13470.057821.109761.2679AID1159526; AID1159528
chromobox protein homolog 1Homo sapiens (human)Potency56.23410.006026.168889.1251AID540317
parathyroid hormone/parathyroid hormone-related peptide receptor precursorHomo sapiens (human)Potency3.16233.548119.542744.6684AID743266
histone deacetylase 9 isoform 3Homo sapiens (human)Potency12.91430.037617.082361.1927AID1259364; AID1259388
histone-lysine N-methyltransferase 2A isoform 2 precursorHomo sapiens (human)Potency39.81070.010323.856763.0957AID2662
nuclear factor erythroid 2-related factor 2 isoform 1Homo sapiens (human)Potency0.09690.000627.21521,122.0200AID651741
Cellular tumor antigen p53Homo sapiens (human)Potency27.38930.002319.595674.0614AID651631
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency0.63100.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Chain A, ODORANT-BINDING PROTEINSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chain A, ODORANT-BINDING PROTEINSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chain B, Odorant-binding ProteinSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chain A, ODORANT-BINDING PROTEINSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chain A, ODORANT-BINDING PROTEINSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chain A, ODORANT-BINDING PROTEINSus scrofa (pig)IC50 (µMol)3.90000.70002.67503.9000AID977608
Chymotrypsinogen ABos taurus (cattle)IC50 (µMol)250.00000.98004.05607.2000AID52776
Beta-lactamaseEscherichia coli K-12IC50 (µMol)90.00000.01502.46578.0000AID43431
Hormone-sensitive lipaseRattus norvegicus (Norway rat)IC50 (µMol)1.10000.37001.27003.2500AID390722
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (133)

Processvia Protein(s)Taxonomy
digestionChymotrypsinogen ABos taurus (cattle)
antibiotic catabolic processBeta-lactamaseEscherichia coli K-12
response to antibioticBeta-lactamaseEscherichia coli K-12
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycle G2/M phase transitionCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
ER overload responseCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
mitophagyCellular tumor antigen p53Homo sapiens (human)
in utero embryonic developmentCellular tumor antigen p53Homo sapiens (human)
somitogenesisCellular tumor antigen p53Homo sapiens (human)
release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
hematopoietic progenitor cell differentiationCellular tumor antigen p53Homo sapiens (human)
T cell proliferation involved in immune responseCellular tumor antigen p53Homo sapiens (human)
B cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
T cell lineage commitmentCellular tumor antigen p53Homo sapiens (human)
response to ischemiaCellular tumor antigen p53Homo sapiens (human)
nucleotide-excision repairCellular tumor antigen p53Homo sapiens (human)
double-strand break repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
protein import into nucleusCellular tumor antigen p53Homo sapiens (human)
autophagyCellular tumor antigen p53Homo sapiens (human)
DNA damage responseCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in cell cycle arrestCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediator resulting in transcription of p21 class mediatorCellular tumor antigen p53Homo sapiens (human)
transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
Ras protein signal transductionCellular tumor antigen p53Homo sapiens (human)
gastrulationCellular tumor antigen p53Homo sapiens (human)
neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of neuroblast proliferationCellular tumor antigen p53Homo sapiens (human)
protein localizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA replicationCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell population proliferationCellular tumor antigen p53Homo sapiens (human)
determination of adult lifespanCellular tumor antigen p53Homo sapiens (human)
mRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
rRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
response to salt stressCellular tumor antigen p53Homo sapiens (human)
response to inorganic substanceCellular tumor antigen p53Homo sapiens (human)
response to X-rayCellular tumor antigen p53Homo sapiens (human)
response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
positive regulation of gene expressionCellular tumor antigen p53Homo sapiens (human)
cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of cardiac muscle cell apoptotic processCellular tumor antigen p53Homo sapiens (human)
glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
viral processCellular tumor antigen p53Homo sapiens (human)
glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
cerebellum developmentCellular tumor antigen p53Homo sapiens (human)
negative regulation of cell growthCellular tumor antigen p53Homo sapiens (human)
DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
negative regulation of transforming growth factor beta receptor signaling pathwayCellular tumor antigen p53Homo sapiens (human)
mitotic G1 DNA damage checkpoint signalingCellular tumor antigen p53Homo sapiens (human)
negative regulation of telomere maintenance via telomeraseCellular tumor antigen p53Homo sapiens (human)
T cell differentiation in thymusCellular tumor antigen p53Homo sapiens (human)
tumor necrosis factor-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
regulation of tissue remodelingCellular tumor antigen p53Homo sapiens (human)
cellular response to UVCellular tumor antigen p53Homo sapiens (human)
multicellular organism growthCellular tumor antigen p53Homo sapiens (human)
positive regulation of mitochondrial membrane permeabilityCellular tumor antigen p53Homo sapiens (human)
cellular response to glucose starvationCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to DNA damage by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of apoptotic processCellular tumor antigen p53Homo sapiens (human)
entrainment of circadian clock by photoperiodCellular tumor antigen p53Homo sapiens (human)
mitochondrial DNA repairCellular tumor antigen p53Homo sapiens (human)
regulation of DNA damage response, signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
transcription initiation-coupled chromatin remodelingCellular tumor antigen p53Homo sapiens (human)
negative regulation of proteolysisCellular tumor antigen p53Homo sapiens (human)
negative regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of DNA-templated transcriptionCellular tumor antigen p53Homo sapiens (human)
positive regulation of RNA polymerase II transcription preinitiation complex assemblyCellular tumor antigen p53Homo sapiens (human)
positive regulation of transcription by RNA polymerase IICellular tumor antigen p53Homo sapiens (human)
response to antibioticCellular tumor antigen p53Homo sapiens (human)
fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
negative regulation of fibroblast proliferationCellular tumor antigen p53Homo sapiens (human)
circadian behaviorCellular tumor antigen p53Homo sapiens (human)
bone marrow developmentCellular tumor antigen p53Homo sapiens (human)
embryonic organ developmentCellular tumor antigen p53Homo sapiens (human)
positive regulation of peptidyl-tyrosine phosphorylationCellular tumor antigen p53Homo sapiens (human)
protein stabilizationCellular tumor antigen p53Homo sapiens (human)
negative regulation of helicase activityCellular tumor antigen p53Homo sapiens (human)
protein tetramerizationCellular tumor antigen p53Homo sapiens (human)
chromosome organizationCellular tumor antigen p53Homo sapiens (human)
neuron apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of cell cycleCellular tumor antigen p53Homo sapiens (human)
hematopoietic stem cell differentiationCellular tumor antigen p53Homo sapiens (human)
negative regulation of glial cell proliferationCellular tumor antigen p53Homo sapiens (human)
type II interferon-mediated signaling pathwayCellular tumor antigen p53Homo sapiens (human)
cardiac septum morphogenesisCellular tumor antigen p53Homo sapiens (human)
positive regulation of programmed necrotic cell deathCellular tumor antigen p53Homo sapiens (human)
protein-containing complex assemblyCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to endoplasmic reticulum stressCellular tumor antigen p53Homo sapiens (human)
thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of thymocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
necroptotic processCellular tumor antigen p53Homo sapiens (human)
cellular response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
cellular response to xenobiotic stimulusCellular tumor antigen p53Homo sapiens (human)
cellular response to ionizing radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to gamma radiationCellular tumor antigen p53Homo sapiens (human)
cellular response to UV-CCellular tumor antigen p53Homo sapiens (human)
stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
signal transduction by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
cellular response to actinomycin DCellular tumor antigen p53Homo sapiens (human)
positive regulation of release of cytochrome c from mitochondriaCellular tumor antigen p53Homo sapiens (human)
cellular senescenceCellular tumor antigen p53Homo sapiens (human)
replicative senescenceCellular tumor antigen p53Homo sapiens (human)
oxidative stress-induced premature senescenceCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
oligodendrocyte apoptotic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of execution phase of apoptosisCellular tumor antigen p53Homo sapiens (human)
negative regulation of mitophagyCellular tumor antigen p53Homo sapiens (human)
regulation of mitochondrial membrane permeability involved in apoptotic processCellular tumor antigen p53Homo sapiens (human)
regulation of intrinsic apoptotic signaling pathway by p53 class mediatorCellular tumor antigen p53Homo sapiens (human)
positive regulation of miRNA transcriptionCellular tumor antigen p53Homo sapiens (human)
negative regulation of G1 to G0 transitionCellular tumor antigen p53Homo sapiens (human)
negative regulation of miRNA processingCellular tumor antigen p53Homo sapiens (human)
negative regulation of glucose catabolic process to lactate via pyruvateCellular tumor antigen p53Homo sapiens (human)
negative regulation of pentose-phosphate shuntCellular tumor antigen p53Homo sapiens (human)
intrinsic apoptotic signaling pathway in response to hypoxiaCellular tumor antigen p53Homo sapiens (human)
regulation of fibroblast apoptotic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
positive regulation of reactive oxygen species metabolic processCellular tumor antigen p53Homo sapiens (human)
negative regulation of stem cell proliferationCellular tumor antigen p53Homo sapiens (human)
positive regulation of cellular senescenceCellular tumor antigen p53Homo sapiens (human)
positive regulation of intrinsic apoptotic signaling pathwayCellular tumor antigen p53Homo sapiens (human)
gluconeogenesisMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADH metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
NADP metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
oxaloacetate metabolic processMalate dehydrogenase, cytoplasmicHomo sapiens (human)
tricarboxylic acid cycleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
malate-aspartate shuttleMalate dehydrogenase, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (41)

Processvia Protein(s)Taxonomy
protein bindingChymotrypsinogen ABos taurus (cattle)
serpin family protein bindingChymotrypsinogen ABos taurus (cattle)
beta-lactamase activityBeta-lactamaseEscherichia coli K-12
hydrolase activityBeta-lactamaseEscherichia coli K-12
transcription cis-regulatory region bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
cis-regulatory region sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
core promoter sequence-specific DNA bindingCellular tumor antigen p53Homo sapiens (human)
TFIID-class transcription factor complex bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription repressor activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription activator activity, RNA polymerase II-specificCellular tumor antigen p53Homo sapiens (human)
protease bindingCellular tumor antigen p53Homo sapiens (human)
p53 bindingCellular tumor antigen p53Homo sapiens (human)
DNA bindingCellular tumor antigen p53Homo sapiens (human)
chromatin bindingCellular tumor antigen p53Homo sapiens (human)
DNA-binding transcription factor activityCellular tumor antigen p53Homo sapiens (human)
mRNA 3'-UTR bindingCellular tumor antigen p53Homo sapiens (human)
copper ion bindingCellular tumor antigen p53Homo sapiens (human)
protein bindingCellular tumor antigen p53Homo sapiens (human)
zinc ion bindingCellular tumor antigen p53Homo sapiens (human)
enzyme bindingCellular tumor antigen p53Homo sapiens (human)
receptor tyrosine kinase bindingCellular tumor antigen p53Homo sapiens (human)
ubiquitin protein ligase bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase regulator activityCellular tumor antigen p53Homo sapiens (human)
ATP-dependent DNA/DNA annealing activityCellular tumor antigen p53Homo sapiens (human)
identical protein bindingCellular tumor antigen p53Homo sapiens (human)
histone deacetylase bindingCellular tumor antigen p53Homo sapiens (human)
protein heterodimerization activityCellular tumor antigen p53Homo sapiens (human)
protein-folding chaperone bindingCellular tumor antigen p53Homo sapiens (human)
protein phosphatase 2A bindingCellular tumor antigen p53Homo sapiens (human)
RNA polymerase II-specific DNA-binding transcription factor bindingCellular tumor antigen p53Homo sapiens (human)
14-3-3 protein bindingCellular tumor antigen p53Homo sapiens (human)
MDM2/MDM4 family protein bindingCellular tumor antigen p53Homo sapiens (human)
disordered domain specific bindingCellular tumor antigen p53Homo sapiens (human)
general transcription initiation factor bindingCellular tumor antigen p53Homo sapiens (human)
molecular function activator activityCellular tumor antigen p53Homo sapiens (human)
promoter-specific chromatin bindingCellular tumor antigen p53Homo sapiens (human)
malic enzyme activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
protein bindingMalate dehydrogenase, cytoplasmicHomo sapiens (human)
L-malate dehydrogenase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
diiodophenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
hydroxyphenylpyruvate reductase activityMalate dehydrogenase, cytoplasmicHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (27)

Processvia Protein(s)Taxonomy
extracellular regionChymotrypsinogen ABos taurus (cattle)
serine protease inhibitor complexChymotrypsinogen ABos taurus (cattle)
outer membrane-bounded periplasmic spaceBeta-lactamaseEscherichia coli K-12
periplasmic spaceBeta-lactamaseEscherichia coli K-12
nuclear bodyCellular tumor antigen p53Homo sapiens (human)
nucleusCellular tumor antigen p53Homo sapiens (human)
nucleoplasmCellular tumor antigen p53Homo sapiens (human)
replication forkCellular tumor antigen p53Homo sapiens (human)
nucleolusCellular tumor antigen p53Homo sapiens (human)
cytoplasmCellular tumor antigen p53Homo sapiens (human)
mitochondrionCellular tumor antigen p53Homo sapiens (human)
mitochondrial matrixCellular tumor antigen p53Homo sapiens (human)
endoplasmic reticulumCellular tumor antigen p53Homo sapiens (human)
centrosomeCellular tumor antigen p53Homo sapiens (human)
cytosolCellular tumor antigen p53Homo sapiens (human)
nuclear matrixCellular tumor antigen p53Homo sapiens (human)
PML bodyCellular tumor antigen p53Homo sapiens (human)
transcription repressor complexCellular tumor antigen p53Homo sapiens (human)
site of double-strand breakCellular tumor antigen p53Homo sapiens (human)
germ cell nucleusCellular tumor antigen p53Homo sapiens (human)
chromatinCellular tumor antigen p53Homo sapiens (human)
transcription regulator complexCellular tumor antigen p53Homo sapiens (human)
protein-containing complexCellular tumor antigen p53Homo sapiens (human)
lipid dropletHormone-sensitive lipaseRattus norvegicus (Norway rat)
cytosolHormone-sensitive lipaseRattus norvegicus (Norway rat)
extracellular spaceMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytoplasmMalate dehydrogenase, cytoplasmicHomo sapiens (human)
centrosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
extracellular exosomeMalate dehydrogenase, cytoplasmicHomo sapiens (human)
cytosolMalate dehydrogenase, cytoplasmicHomo sapiens (human)
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (103)

Assay IDTitleYearJournalArticle
AID1347424RapidFire Mass Spectrometry qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347407qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Pharmaceutical Collection2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347425Rhodamine-PBP qHTS Assay for Modulators of WT P53-Induced Phosphatase 1 (WIP1)2019The Journal of biological chemistry, 11-15, Volume: 294, Issue:46
Physiologically relevant orthogonal assays for the discovery of small-molecule modulators of WIP1 phosphatase in high-throughput screens.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID504749qHTS profiling for inhibitors of Plasmodium falciparum proliferation2011Science (New York, N.Y.), Aug-05, Volume: 333, Issue:6043
Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID218572Fold increase in IC50 vs beta-lactamase with 10x increased enzyme2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1577841Inhibition of Cys5-LDEETGEFL-NH2 binding to recombinant human KEAP1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) measured after 10 to 15 mins in presence of 0.01% Triton X-100 by fluorescence polarization assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
AID1102087Acaricidal activity against Dermatophagoides pteronyssinus after 24 hr by fabric disk assay2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1196166Self-aggregation activity of the compound in PBS assessed as derived light scattering count rate at 25 uM at pH 7.4 (Rvb = 15.5 +/- 0.4 kilocount/sec)2015European journal of medicinal chemistry, Mar-06, Volume: 92Functionalized tetrahydro-1H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity.
AID1103187Acaricidal activity against 7 to 10 day-old Dermatophagoides pteronyssinus adult after 24 hr by microscopy2004Journal of agricultural and food chemistry, May-19, Volume: 52, Issue:10
Acaricidal activity of constituents identified in Foeniculum vulgare fruit oil against Dermatophagoides spp. (Acari: Pyroglyphidae).
AID52773Fold increase in IC50 vs chymotrypsinogen with 0.2 mg/ml saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID362091Antagonist activity at HA-tagged mouse AT1a angiotensin 2 receptor expressed in HEK293T cells assessed as decrease in angiotensin 2-induced intracellular calcium uptake2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID1598718Binding affinity to Triton-X 100 assessed as change in chemical shift at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID1081891Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 2 hr post compound exposure at 0.2 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1081895Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 2 hr post compound exposure at 0.00002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID362093Displacement of [125I]angiotensin 2 from AT1 angiotensin 2 receptor expressed in CHO cells at 100 uM2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID362096Displacement of [125I]CGP-42112A from AT2 angiotensin 2 receptor expressed in HeLa cells at 300 uM2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID52776Compound was tested for the inhibition of Chymotrypsinogen2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1103188Acaricidal activity against 7 to 10 day-old Dermatophagoides farinae adult after 24 hr by microscopy2004Journal of agricultural and food chemistry, May-19, Volume: 52, Issue:10
Acaricidal activity of constituents identified in Foeniculum vulgare fruit oil against Dermatophagoides spp. (Acari: Pyroglyphidae).
AID1577815Inhibition of Cys5-LDEETGEFL-NH2 binding to recombinant human KEAP1 Kelch domain (321 to 609 residues) expressed in Escherichia coli BL21 (DE3) measured after 10 to 15 mins by fluorescence polarization assay2019Journal of medicinal chemistry, 09-12, Volume: 62, Issue:17
A Comparative Assessment Study of Known Small-Molecule Keap1-Nrf2 Protein-Protein Interaction Inhibitors: Chemical Synthesis, Binding Properties, and Cellular Activity.
AID1053268Inhibition of COX-2 (unknown origin) using arachidonic acid as substrate assessed as formation of prostanoid products at 500 uM preincubated for 10 mins prior to substrate addition measured after 2 mins by Ellman's method relative to control2013Journal of medicinal chemistry, Nov-14, Volume: 56, Issue:21
Experimental confirmation of new drug-target interactions predicted by Drug Profile Matching.
AID1081888Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 4 hr post compound exposure at 0.002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1102089Acaricidal activity against Dermatophagoides farinae after 24 hr by fabric disk assay2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1081885Lipophilicity, logP of the compound2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID106656Fold decrease in IC50 vs malate dehydrogenase (MDH) on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID106799Fold increase in IC50 vs malate dehydrogenase (MDH) with 1 mg/ml saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1102092Acaricidal activity against Dermatophagoides farinae assessed as mortality at 12.7 ug/cm2 after 48 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1102055Acaricidal activity against Dermatophagoides pteronyssinus assessed as mortality at 9.6 to 12.7 ug/cm2 after 24 to 72 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID1081889Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 4 hr post compound exposure at 0.0002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1196165Self-aggregation of the compound in PBS assessed as derived light scattering count rate at 250 uM at pH 7.4 (Rvb = 15.5 +/- 0.4 kilocount/sec)2015European journal of medicinal chemistry, Mar-06, Volume: 92Functionalized tetrahydro-1H-pyrido[4,3-b]indoles: a novel chemotype with Sirtuin 2 inhibitory activity.
AID218693Fold increase in IC50 vs beta-lactamaase with 1 mg/mL saponin2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID362097Antihypertensive activity in Std:ddY mouse assessed as inhibition of increase of angiotensin 2-induced systolic arterial pressure at 2 and 10 mg/kg, po after 30 mins2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID1647668Antibacterial activity against Escherichia coli at 5 mM incubated for 18 hrs by AlamarBlue assay
AID977599Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID43431Compound was tested for the inhibition of beta-lactamase2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1081892Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 2 hr post compound exposure at 0.02 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1102061Acaricidal activity against Dermatophagoides farinae assessed as mortality at 12.7 ug/cm2 after 72 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID43563Fold decrease in IC50 vs beta-lactamase on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID52778Fold decrease in IC50 vs chymotrypsinogen on pre-incubation2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1081887Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 4 hr post compound exposure at 0.02 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1102076Acaricidal activity against Dermatophagoides farinae assessed as mortality at 9.6 ug/cm2 after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID106801Inhibition of malate dehydrogenase (MDH)2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1081890Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 4 hr post compound exposure at 0.00002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1102077Acaricidal activity against Dermatophagoides farinae assessed as mortality at 12.7 ug/cm2 after 24 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID362094Displacement of [125I]angiotensin 2 from AT1 angiotensin 2 receptor expressed in CHO cells at 300 uM2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID390724Inhibition of HSL in Wistar rat isolated fat cells at 10 uM by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID1081894Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 2 hr post compound exposure at 0.0002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1598719Binding affinity to Triton-X 100 assessed as line broadening at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID1102060Acaricidal activity against Dermatophagoides farinae assessed as mortality at 9.6 ug/cm2 after 72 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID355880Pesticidal activity against Dermatophagoides pteronyssinus after 24 hrs2003Journal of natural products, May, Volume: 66, Issue:5
Acaricidal activity of tonka bean extracts. Synthesis and structure-activity relationships of bioactive derivatives.
AID977602Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM2013Molecular pharmacology, Jun, Volume: 83, Issue:6
Structure-based identification of OATP1B1/3 inhibitors.
AID1081886Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 4 hr post compound exposure at 0.2 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID362092Cytotoxicity against HEK293T cells expressing HA-tagged mouse AT1a angiotensin 2 receptor up to 100 ug/ml after 24 hrs by trypan blue dye exclusion assay2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID390722Inhibition of HSL in Wistar rat isolated fat cells by spectrophotometric assay2008Journal of medicinal chemistry, Oct-23, Volume: 51, Issue:20
Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors.
AID362095Displacement of [125I]CGP-42112A from AT2 angiotensin 2 receptor expressed in HeLa cells at 100 uM2008Bioorganic & medicinal chemistry, Aug-15, Volume: 16, Issue:16
Inhibitory effects of benzyl benzoate and its derivatives on angiotensin II-induced hypertension.
AID1598717Binding affinity to Triton-X 100 assessed as peak intensity loss at 150 uM by 1H-NMR spectra analysis2019Journal of medicinal chemistry, 05-23, Volume: 62, Issue:10
Mechanisms of Specific versus Nonspecific Interactions of Aggregation-Prone Inhibitors and Attenuators.
AID235784Topical dosage on sterol scabies2003Journal of medicinal chemistry, Oct-09, Volume: 46, Issue:21
Identification and prediction of promiscuous aggregating inhibitors among known drugs.
AID1081893Repellent activity against Tribolium castaneum (red flour beetle) assessed as induction of repellency measured 2 hr post compound exposure at 0.002 uL/cm2 using 15% compound formulation2011Journal of agricultural and food chemistry, Mar-09, Volume: 59, Issue:5
Repellent activity of essential oils and some of their individual constituents against Tribolium castaneum herbst.
AID1102068Acaricidal activity against Dermatophagoides farinae assessed as mortality at 9.6 ug/cm2 after 48 hr by fabric disk assay relative to untreated control2003Journal of agricultural and food chemistry, Feb-12, Volume: 51, Issue:4
Acaricidal activity of clove bud oil compounds against Dermatophagoides farinae and Dermatophagoides pteronyssinus (Acari: Pyroglyphidae).
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1811Experimentally measured binding affinity data derived from PDB2000Journal of molecular biology, Jun-30, Volume: 300, Issue:1
Complexes of porcine odorant binding protein with odorant molecules belonging to different chemical classes.
AID977608Experimentally measured binding affinity data (IC50) for protein-ligand complexes derived from PDB2000Journal of molecular biology, Jun-30, Volume: 300, Issue:1
Complexes of porcine odorant binding protein with odorant molecules belonging to different chemical classes.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1159550Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening2015Nature cell biology, Nov, Volume: 17, Issue:11
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (271)

TimeframeStudies, This Drug (%)All Drugs %
pre-199052 (19.19)18.7374
1990's49 (18.08)18.2507
2000's75 (27.68)29.6817
2010's71 (26.20)24.3611
2020's24 (8.86)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 56.37

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index56.37 (24.57)
Research Supply Index5.78 (2.92)
Research Growth Index4.63 (4.65)
Search Engine Demand Index180.84 (26.88)
Search Engine Supply Index3.85 (0.95)

This Compound (56.37)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials35 (12.11%)5.53%
Reviews18 (6.23%)6.00%
Case Studies26 (9.00%)4.05%
Observational5 (1.73%)0.25%
Other205 (70.93%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]